New antibody drug YK012 takes aim at Hard-to-Treat lymphoma
NCT ID NCT06565689
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study is testing a new drug called YK012 in 48 adults with relapsed or refractory B-cell non-Hodgkin lymphoma. YK012 is a bispecific antibody designed to help the body's immune T cells recognize and kill cancer B cells. The main goals are to check the drug's safety, find the right dose, and see early signs of effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
YK012 (a bispecific antibody that helps immune cells attack cancer cells)
What this could lead to
If successful, this could lead to a new treatment option for people with B-cell lymphoma that has not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 48 participants, so it is primarily testing safety and dosing. The drug may not work or could cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••